Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E B MOORE

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Cancer|March 1, 1979
A slim 198gold-grain implanter loaded with standard Royal Marsden 14-grain magazinesL Delclos, E B Moore
Seminars in Nuclear Medicine|October 6, 2009
Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearanceGlen M Blake, Amelia E B Moore, Ignac Fogelman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearanceAmelia E B Moore, Glen M Blake, Ignac Fogelman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood samplingAmelia E B Moore, Glen M Blake, Ignac Fogelman
Nuclear Medicine Communications|February 1, 2007
A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentrationAmelia E B Moore, Glen M Blake, Ignac Fogelman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2003
Validation of ultrafiltration as a method of measuring free 99mTc-MDPAmelia E B Moore, Sharon F Hain, Glen M Blake, et al.
Clinical Endocrinology|December 31, 2015
Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic settingJ Roberts, C Castro, A E B Moore, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2002
Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10 percentAmelia E B Moore, So-Jin Park-Holohan, Glen M Blake, et al.
Nuclear Medicine Communications|June 19, 2003
A direct in vivo measurement of 99mTc-methylene diphosphonate protein bindingG M Blake, A E B Moore, S J Park-Holohan, et al.
Endocrine Research|April 14, 2018
Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D statusJ Mok, C Brown, A E B Moore, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Cancer|March 1, 1979
A slim 198gold-grain implanter loaded with standard Royal Marsden 14-grain magazinesL Delclos, E B Moore
Seminars in Nuclear Medicine|October 6, 2009
Quantitative studies of bone using (99m)Tc-methylene diphosphonate skeletal plasma clearanceGlen M Blake, Amelia E B Moore, Ignac Fogelman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2006
Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearanceAmelia E B Moore, Glen M Blake, Ignac Fogelman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 22, 2008
Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood samplingAmelia E B Moore, Glen M Blake, Ignac Fogelman
Nuclear Medicine Communications|February 1, 2007
A study to determine the dependence of 99mTc-MDP protein binding on plasma clearance and serum albumin concentrationAmelia E B Moore, Glen M Blake, Ignac Fogelman
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2003
Validation of ultrafiltration as a method of measuring free 99mTc-MDPAmelia E B Moore, Sharon F Hain, Glen M Blake, et al.
Clinical Endocrinology|December 31, 2015
Changes in bone mineral density and bone turnover in patients on 'drug holiday' following bisphosphonate therapy: real-life clinic settingJ Roberts, C Castro, A E B Moore, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 17, 2002
Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10 percentAmelia E B Moore, So-Jin Park-Holohan, Glen M Blake, et al.
Nuclear Medicine Communications|June 19, 2003
A direct in vivo measurement of 99mTc-methylene diphosphonate protein bindingG M Blake, A E B Moore, S J Park-Holohan, et al.
Endocrine Research|April 14, 2018
Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D statusJ Mok, C Brown, A E B Moore, et al.
Pageof 4